PT1210357E - Oligonucleótido-tiofosforamidatos n3'→p5': sua síntese e utilização - Google Patents

Oligonucleótido-tiofosforamidatos n3'→p5': sua síntese e utilização Download PDF

Info

Publication number: PT1210357E
Authority: PT; Portugal
Prior art keywords: oligonucleotides; oligonucleotide; thiophosphoramidates; synthesis; inventive
Prior art date: 1999-09-10

Application number

PT00961689T

Other languages

English (en)

Inventor

Sergei Gryaznov

Krisztina Pongracz

Tracy Matray

Original Assignee

Geron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-10

Filing date

2000-09-08

Publication date

2008-06-11

2000-09-08 Application filed by Geron Corp filed Critical Geron Corp

2008-06-11 Publication of PT1210357E publication Critical patent/PT1210357E/pt

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 5
230000015572 biosynthetic process Effects 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
230000004570 RNA-binding Effects 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000008298 phosphoramidates Chemical class 0.000 abstract 1
230000002194 synthesizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PT00961689T 1999-09-10 2000-09-08 Oligonucleótido-tiofosforamidatos n3'→p5': sua síntese e utilização PT1210357E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15320199P	1999-09-10	1999-09-10
US16044499P	1999-10-19	1999-10-19

Publications (1)

Publication Number	Publication Date
PT1210357E true PT1210357E (pt)	2008-06-11

Family

ID=26850281

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT00961689T PT1210357E (pt)	1999-09-10	2000-09-08	Oligonucleótido-tiofosforamidatos n3'→p5': sua síntese e utilização

Country Status (17)

Country	Link
US (5)	US6608036B1 (pt)
EP (2)	EP1992634A1 (pt)
JP (2)	JP4267233B2 (pt)
KR (2)	KR100858465B1 (pt)
CN (1)	CN1317291C (pt)
AT (1)	ATE391134T1 (pt)
AU (2)	AU767646B2 (pt)
CA (1)	CA2382521C (pt)
CY (1)	CY1108158T1 (pt)
DE (1)	DE60038495T2 (pt)
DK (1)	DK1210357T3 (pt)
ES (1)	ES2302701T3 (pt)
HK (1)	HK1049339B (pt)
IL (2)	IL148304A0 (pt)
MX (1)	MXPA02002577A (pt)
PT (1)	PT1210357E (pt)
WO (1)	WO2001018015A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL107150A0 (en) *	1992-09-29	1993-12-28	Isis Pharmaceuticals Inc	Oligonucleotides having a conserved g4 core sequence
US20030032610A1 (en) *	1996-06-03	2003-02-13	Gilchrest Barbara A.	Method to inhibit cell growth using oligonucleotides
AU758956B2 (en)	1999-02-12	2003-04-03	Daiichi Sankyo Company, Limited	Novel nucleosides and oligonucleotide analogues
PT1210357E (pt) *	1999-09-10	2008-06-11	Geron Corp	Oligonucleótido-tiofosforamidatos n3'→p5': sua síntese e utilização
EP2363133A1 (en)	2000-03-31	2011-09-07	Trustees of Boston University	Composition comprising DNA fragments and medical and cosmetic uses thereof
AU2003244338C1 (en) *	2001-03-23	2008-07-24	Geron Corporation	Oligonucleotide conjugates
US7563618B2 (en) *	2001-03-23	2009-07-21	Geron Corporation	Oligonucleotide conjugates
WO2002077184A2 (en)	2001-03-23	2002-10-03	Geron Corporation	Oligonucleotide conjugates
DE10159904A1 (de) *	2001-12-06	2003-07-03	Adnagen Ag	Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
WO2004037842A1 (ja) *	2002-10-23	2004-05-06	Sankyo Company, Limited	糖部ｓ型配座の新規人工核酸
KR101312389B1 (ko)	2003-06-23	2013-09-27	제론 코포레이션	텔로머라제 활성을 증가시키기 위한 조성물 및 방법
WO2005000248A2 (en)	2003-06-25	2005-01-06	Geron Corporation	Compositions and methods for skin conditioning
ES2775525T3 (es)	2003-09-09	2020-07-27	Geron Corp	Oligonucleótidos modificados para la inhibición de la telomerasa
US9133233B2 (en)	2003-11-04	2015-09-15	Geron Corporation	RNA amidates and thioamidates for RNAi
EP1783216A1 (en) *	2004-05-28	2007-05-09	Sankyo Company, Limited	Telomerase-inhibitory ena oligonucleotide
CN100558739C (zh)	2004-07-02	2009-11-11	杰龙公司	合成被保护的3’-氨基核苷单体
EP1828217A2 (en) *	2004-12-16	2007-09-05	Febit Biotech GmbH	Polymerase-independent analysis of the sequence of polynucleotides
WO2006113426A2 (en) *	2005-04-15	2006-10-26	Geron Corporation	Cancer treatment by combined inhibition of telomerase and tubulin activities
US8153604B2 (en) *	2006-04-24	2012-04-10	Geron Corporation	CNS-tumor treatment method and composition
ES2533264T3 (es)	2006-10-30	2015-04-08	Geron Corporation	Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer
WO2008094640A2 (en)	2007-01-30	2008-08-07	Geron Corporation	Compounds having anti-adhesive effects on cancer cells
US8011527B2 (en) *	2007-08-10	2011-09-06	Rexam Beverage Can Company	Can end with countersink
NO3029154T3 (pt)	2008-10-17	2018-03-03
MX2011007364A (es)	2009-01-09	2012-02-28	Univ Cardiff	Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
CA2831613A1 (en)	2011-03-31	2012-10-04	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US9593137B2 (en)	2011-12-22	2017-03-14	Geron Corporation	Guanine analogs as telomerase substrates and telomere length affectors
EP2830991A1 (en)	2012-03-26	2015-02-04	President and Fellows of Harvard College	Lipid-coated nucleic acid nanostructures of defined shape
US9228189B2 (en)	2012-10-26	2016-01-05	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
CA3201145A1 (en) *	2012-10-26	2014-05-01	Geron Corporation	C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US9200327B2 (en)	2012-11-30	2015-12-01	Geron Corporation	Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3578663A1 (en)	2013-03-15	2019-12-11	ModernaTX, Inc.	Manufacturing methods for production of rna transcripts
US10590161B2 (en)	2013-03-15	2020-03-17	Modernatx, Inc.	Ion exchange purification of mRNA
EP2971165A4 (en)	2013-03-15	2016-11-23	Moderna Therapeutics Inc	DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
WO2014152031A1 (en)	2013-03-15	2014-09-25	Moderna Therapeutics, Inc.	Ribonucleic acid purification
CN103382212B (zh) *	2013-07-06	2016-08-31	中国科学院成都生物研究所	5′位改性嘌呤霉素化合物及其制备方法和用途
LT3019619T (lt)	2013-07-11	2021-12-10	Modernatx, Inc.	Sintetinius polinukleotidus apimančios kompozicijos, koduojančios susijusius su crispr baltymus ir sintetines sgrnas, ir jų naudojimo būdai
EP3868772A1 (en)	2013-09-30	2021-08-25	Geron Corporation	Phosphorodiamidate backbone linkage for oligonucleotides
US10385088B2 (en)	2013-10-02	2019-08-20	Modernatx, Inc.	Polynucleotide molecules and uses thereof
JP2017505104A (ja) *	2013-11-08	2017-02-16	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	インビボにおける薬剤送達のための核酸ナノ構造体
US10900083B2 (en)	2013-12-20	2021-01-26	The General Hospital Corporation	Methods and assays relating to circulating tumor cells
JOP20200257A1 (ar) *	2014-05-01	2017-06-16	Geron Corp	تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
EP3157573A4 (en)	2014-06-19	2018-02-21	Moderna Therapeutics, Inc.	Alternative nucleic acid molecules and uses thereof
EP3169335B8 (en)	2014-07-16	2019-10-09	ModernaTX, Inc.	Circular polynucleotides
EP3169693B1 (en) *	2014-07-16	2022-03-09	ModernaTX, Inc.	Chimeric polynucleotides
MA42569B1 (fr) *	2015-04-23	2020-08-31	Geron Corp	Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
US11434486B2 (en)	2015-09-17	2022-09-06	Modernatx, Inc.	Polynucleotides containing a morpholino linker
PL3350333T3 (pl)	2015-09-17	2022-03-07	Modernatx, Inc.	Polinukleotydy zawierające region stabilizujący ogon
EP3318276A1 (en)	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
BR112019004911A2 (pt) *	2016-09-14	2019-06-25	Janssen Biopharma Inc	oligonucleotídeos modificados e métodos de uso
WO2018057430A1 (en) *	2016-09-20	2018-03-29	The Regents Of The University Of Colorado, A Body Corporate	Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
EP3538654A1 (en) *	2016-11-11	2019-09-18	Janssen BioPharma, Inc.	Oligonucleotide targeting strategy for hbv cccdna
WO2018221735A1 (ja) *	2017-06-02	2018-12-06	富田製薬株式会社	新規オリゴヌクレオチド
CA3195922A1 (en) *	2017-07-10	2019-01-17	Geron Corporation	Improved process for preparing imetelstat
CA3075718A1 (en) *	2017-09-14	2019-03-21	Janssen Biopharma, Inc.	Modified nucleoside phosphoramidites
MX2020009532A (es) *	2018-03-13	2020-10-05	Janssen Pharmaceutica Nv	Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
WO2019226990A1 (en) *	2018-05-25	2019-11-28	New York Institute Of Technology	Direct nucleic acid sequencing method
CN112384521B (zh)	2018-07-05	2024-05-03	安捷伦科技有限公司	用于寡核苷酸合成的双重偶联方法
US20230250125A1 (en)	2020-04-01	2023-08-10	Janssen Biopharma, Inc.	Nucleic acid polymers
CN118388567A (zh) *	2024-06-26	2024-07-26	广州表观生物科技有限公司	一种特异性靶向酪氨酸酶、制备方法及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4394448A (en)	1978-02-24	1983-07-19	Szoka Jr Francis C	Method of inserting DNA into living cells
US4647529A (en)	1984-06-01	1987-03-03	Rodland Karin D	Hybridization method of detecting nucleic acid sequences with probe containing thionucleotide
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US5124246A (en)	1987-10-15	1992-06-23	Chiron Corporation	Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5109124A (en)	1988-06-01	1992-04-28	Biogen, Inc.	Nucleic acid probe linked to a label having a terminal cysteine
US5501959A (en)	1989-01-17	1996-03-26	Alamar Biosciences Laboratory, Inc.	Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en)	1989-06-07	1995-06-13	Affymax Technologies N.V.	Very large scale immobilized polymer synthesis
US5506212A (en)	1990-01-11	1996-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides with substantially chirally pure phosphorothioate linkages
IL99120A0 (en) *	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5412087A (en)	1992-04-24	1995-05-02	Affymax Technologies N.V.	Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US6017895A (en)	1992-02-10	2000-01-25	Genzyme Corporation	Oligonucleotides possessing zwitterionic moieties
US5645986A (en) *	1992-05-13	1997-07-08	Board Of Reagents, The University Of Texas System	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5476925A (en)	1993-02-01	1995-12-19	Northwestern University	Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5654286A (en) *	1993-05-12	1997-08-05	Hostetler; Karl Y.	Nucleotides for topical treatment of psoriasis, and methods for using same
EP0706531A4 (en)	1993-07-02	1998-11-25	Lynx Therapeutics Inc	SYNTHESIS OF BRANCHED NUCLEIC ACIDS
US5637684A (en)	1994-02-23	1997-06-10	Isis Pharmaceuticals, Inc.	Phosphoramidate and phosphorothioamidate oligomeric compounds
US5599922A (en)	1994-03-18	1997-02-04	Lynx Therapeutics, Inc.	Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5965720A (en) *	1994-03-18	1999-10-12	Lynx Therapeutics, Inc.	Oligonucleotide N3'→P5' phosphoramidates
US5726297A (en)	1994-03-18	1998-03-10	Lynx Therapeutics, Inc.	Oligodeoxyribonucleotide N3' P5' phosphoramidates
EP1293565A3 (en)	1994-07-07	2004-05-12	Geron Corporation	Mammalian telomerase RNA component
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5972605A (en)	1994-07-07	1999-10-26	Geron Corporation	Assays for regulators of mammalian telomerase expression
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5776679A (en)	1994-07-07	1998-07-07	Geron Corporation	Assays for the DNA component of human telomerase
US5643890A (en) *	1995-01-31	1997-07-01	The Board Of Regents Of The University Of Nebraska	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US6004939A (en)	1995-07-06	1999-12-21	Ctrc Research Foundation Board Of Regents	Methods for modulation and inhibition of telomerase
US5968506A (en) *	1995-08-04	1999-10-19	Geron Corporation	Purified telomerase
US5856096A (en) *	1995-09-20	1999-01-05	Ctrc Research Foundation	Rapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activities
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US5684143A (en)	1996-02-21	1997-11-04	Lynx Therapeutics, Inc.	Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
AU6321696A (en)	1996-04-05	1997-10-29	German Viktorovich Demidov	Transportation power unit with energetic module
US6015710A (en) *	1996-04-09	2000-01-18	The University Of Texas System	Modulation of mammalian telomerase by peptide nucleic acids
WO1997037691A1 (en)	1996-04-10	1997-10-16	Lynx Therapeutics, Inc.	Telomerase inhibitors
EP0912761A4 (en) *	1996-05-29	2004-06-09	Cornell Res Foundation Inc	DETERMINATION OF DIFFERENCES IN THE NUCLEIC ACID SEQUENCE BY MEANS OF A COMBINATION OF LIGASE DETERMINATION AND POLYMERASE CHAIN REACTION
US6093809A (en)	1996-10-01	2000-07-25	University Technology Corporation	Telomerase
EP0932686A2 (en)	1996-10-01	1999-08-04	Geron Corporation	Telomerase reverse transcriptase
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
DE19720151A1 (de) *	1997-05-02	1998-11-05	Max Delbrueck Centrum	Chimäre Oligonucleotide und ihre Verwendung
JPH11228451A (ja) *	1998-02-10	1999-08-24	Kureha Chem Ind Co Ltd	抗癌性増強医薬組成物
PT1210357E (pt) *	1999-09-10	2008-06-11	Geron Corp	Oligonucleótido-tiofosforamidatos n3'→p5': sua síntese e utilização
AU2001249723A1 (en)	2000-03-31	2001-10-15	Geron Corporation	Telomerase inhibitor polynucleotides
US6342358B1 (en)	2000-08-24	2002-01-29	The Regents Of The University Of California	Human telomerase RNA elements
US7354706B2 (en) *	2003-09-09	2008-04-08	The Regents Of The University Of Colorado, A Body Corporate	Use of photopolymerization for amplification and detection of a molecular recognition event

2000
- 2000-09-08 PT PT00961689T patent/PT1210357E/pt unknown
- 2000-09-08 DK DK00961689T patent/DK1210357T3/da active
- 2000-09-08 DE DE60038495T patent/DE60038495T2/de not_active Expired - Lifetime
- 2000-09-08 IL IL14830400A patent/IL148304A0/xx active IP Right Grant
- 2000-09-08 KR KR1020027003225A patent/KR100858465B1/ko active IP Right Grant
- 2000-09-08 CN CNB008127298A patent/CN1317291C/zh not_active Expired - Lifetime
- 2000-09-08 EP EP08075163A patent/EP1992634A1/en not_active Withdrawn
- 2000-09-08 US US09/657,445 patent/US6608036B1/en not_active Expired - Lifetime
- 2000-09-08 WO PCT/US2000/024688 patent/WO2001018015A1/en active IP Right Grant
- 2000-09-08 JP JP2001522238A patent/JP4267233B2/ja not_active Expired - Lifetime
- 2000-09-08 MX MXPA02002577A patent/MXPA02002577A/es active IP Right Grant
- 2000-09-08 ES ES00961689T patent/ES2302701T3/es not_active Expired - Lifetime
- 2000-09-08 AT AT00961689T patent/ATE391134T1/de active
- 2000-09-08 CA CA002382521A patent/CA2382521C/en not_active Expired - Lifetime
- 2000-09-08 AU AU73609/00A patent/AU767646B2/en not_active Expired
- 2000-09-08 EP EP00961689A patent/EP1210357B1/en not_active Expired - Lifetime
- 2000-09-08 KR KR1020077024593A patent/KR20070112295A/ko not_active Application Discontinuation
2002
- 2002-02-21 IL IL148304A patent/IL148304A/en unknown
- 2002-12-05 HK HK02108873.3A patent/HK1049339B/zh not_active IP Right Cessation
2003
- 2003-06-17 US US10/463,076 patent/US6835826B2/en not_active Expired - Lifetime
- 2003-11-21 AU AU2003262453A patent/AU2003262453A1/en not_active Abandoned
2004
- 2004-10-18 US US10/967,755 patent/US7138383B2/en not_active Expired - Lifetime
2006
- 2006-10-25 US US11/586,993 patent/US20070037770A1/en not_active Abandoned
2008
- 2008-06-26 CY CY20081100672T patent/CY1108158T1/el unknown
- 2008-08-12 JP JP2008208285A patent/JP2009046483A/ja not_active Withdrawn
2014
- 2014-07-09 US US14/327,447 patent/US20140349292A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20070037770A1 (en)	2007-02-15
ATE391134T1 (de)	2008-04-15
CN1317291C (zh)	2007-05-23
IL148304A0 (en)	2002-09-12
KR100858465B1 (ko)	2008-09-16
DE60038495T2 (de)	2009-04-09
KR20070112295A (ko)	2007-11-22
DE60038495D1 (de)	2008-05-15
KR20020092909A (ko)	2002-12-12
US6835826B2 (en)	2004-12-28
MXPA02002577A (es)	2003-10-14
US20030212032A1 (en)	2003-11-13
WO2001018015A1 (en)	2001-03-15
AU767646B2 (en)	2003-11-20
AU7360900A (en)	2001-04-10
HK1049339A1 (en)	2003-05-09
ES2302701T3 (es)	2008-08-01
US20140349292A1 (en)	2014-11-27
DK1210357T3 (da)	2008-07-21
CN1373768A (zh)	2002-10-09
EP1210357A1 (en)	2002-06-05
JP2009046483A (ja)	2009-03-05
AU2003262453A1 (en)	2003-12-18
US20050049408A1 (en)	2005-03-03
CA2382521C (en)	2009-08-25
HK1049339B (zh)	2008-06-27
US6608036B1 (en)	2003-08-19
CY1108158T1 (el)	2014-02-12
JP2003513887A (ja)	2003-04-15
US7138383B2 (en)	2006-11-21
JP4267233B2 (ja)	2009-05-27
IL148304A (en)	2007-10-31
CA2382521A1 (en)	2001-03-15
EP1992634A1 (en)	2008-11-19
EP1210357B1 (en)	2008-04-02

Publication	Publication Date	Title
PT1210357E (pt)	2008-06-11	Oligonucleótido-tiofosforamidatos n3'→p5': sua síntese e utilização
KR0133131B1 (en)	1998-04-14	Peptide nucleic acids
NO963891D0 (no)	1996-09-17	Oligonukleotid N3'-> P5' fosforamidater: Syntese og forbindelser; hybridiserings- og nukleaseresistanse-egenskaper
CA2223678A1 (en)	1996-10-17	Covalently linked oligonucleotide minor groove binder conjugates
CY1105109T1 (el)	2009-11-04	Διαδικασια για την παρασκευη μικρου μοριακου βαρους πολυαιθυλενιμινης
CA2394984A1 (en)	2001-06-21	Novel plant expression constructs
PT937098E (pt)	2002-12-31	Clonagem recombinatoria in vitro utilizando locais de recombinacao modificados
DE69432586D1 (de)	2003-06-05	Methode zum generieren von einzelsträngigen dna molekülen
ES2148136T3 (es)	2000-10-16	Nuevos conjugados de proteina-polication.
DK0804456T3 (da)	2002-12-02	Peptid-nukleinsyre-konjugater
ATE232880T1 (de)	2003-03-15	Neue nucleotidanaloga
BR9913360A (pt)	2001-07-03	Oxidase de urato
PT92640A (pt)	1990-06-29	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules by forming a colinear triplex the synthetic oligonucleotides and methods of use
EP1108724A3 (en)	2003-01-08	Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
DK2351844T3 (da)	2014-09-22	Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler
ATE333261T1 (de)	2006-08-15	Klebstoffzusammensetzung und verfahren zu ihrer herstellung
EP1762619A3 (en)	2007-05-09	Multiple-tumor aberrant growth genes
DE3675481D1 (de)	1990-12-13	Verbindungen, enthaltend eine oligonukleotide sequenz, gebunden an eine interkalierungsverbindung und an eine aktivierbare chemische verbindung, ihre synthese und verwendungen als artifizielle sequenzspezifische nuklease.
CY1106041T1 (el)	2011-04-06	Καινοφανης συλλεκτινη
CA2382631A1 (en)	2001-03-08	Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
WO1996015240A3 (en)	1996-08-15	Ribozyme analogs
WO2003031459A3 (de)	2003-11-13	Modulation der expression stat-1-abhängiger gene
ATE366818T1 (de)	2007-08-15	Hirse-spezifische verzwergungsgene und verfahren ihrer anwendung
DE59905513D1 (de)	2003-06-12	Antisense-oligonukleotid zur hemmung der expression des adhäsionsmoleküls very late antigen 4 (vla-4) in menschlichen zellen
EP0777730A4 (en)	1999-10-13	DNA VECTOR FOR BONE-SPECIFIC GENE EXPRESSION